dsm-firmenich Sells Animal Nutrition Unit to CVC for €2.2B, Completes Strategic Pivot
Event summary
- dsm-firmenich sells its Animal Nutrition & Health (ANH) business to CVC Capital Partners for €2.2B, including a €0.5B earnout.
- The deal includes a 20% equity stake for dsm-firmenich in the divested ANH companies and a long-term vitamins supply agreement.
- ANH generated €3.5B in annualized net sales in 2025 and will be split into two standalone companies.
- dsm-firmenich plans to launch a €0.5B share repurchase program and adopt a 'stable to preferably rising' dividend policy.
- The transaction is expected to close by the end of 2026, subject to regulatory approvals and other conditions.
The big picture
This divestiture marks the final step in dsm-firmenich's strategic shift to focus on consumer-facing nutrition, health, and beauty segments. The €2.2B deal with CVC, following the €1.5B sale of Feed Enzymes to Novonesis in 2025, underscores the company's commitment to streamlining its portfolio. The transaction also highlights the growing private equity interest in specialized animal nutrition and health assets, reflecting broader industry trends toward consolidation and vertical integration.
What we're watching
- Execution Risk
- Whether dsm-firmenich can successfully separate ANH into two standalone companies and complete the transaction by year-end 2026.
- Capital Allocation
- How dsm-firmenich deploys the €0.5B share repurchase program and maintains its dividend policy.
- Strategic Focus
- The pace at which dsm-firmenich integrates its remaining nutrition, health, and beauty businesses.
Related topics